Homepage>Company>Media>Pharma News>2018>The EU approved Sanofi’s Cablivi (caplacizumab) as the first antibody therapeutic to treat acquired thrombotic thrombocytopenic purpura (aTTP) on Friday
The EU approved Sanofi’s Cablivi (caplacizumab) as the first antibody therapeutic to treat acquired thrombotic thrombocytopenic purpura (aTTP) on Friday